Pegaptanib sodium for the treatment of proliferative diabetic retinopathy and diabetic macular edema.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Current Diabetes Reviews

• Publication date

  2009-01-31

• Fields of study

  Medicine

• Identifiers
  DOI 10.2174/157339909787314158PMID 19199896
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pegaptanib Sodium (Macugen®) as an Adjunct in the Management of Refractory Proliferative Diabetic Retinopathy and Clinically Significant Macular Edema

  2007cited by this paper
• Clinical validation of a link between TNF-α and the glycosylation enzyme core 2 GlcNAc-T and the relationship of this link to diabetic retinopathy

  2006cited by this paper
• Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals.

  2006cited by this paper
• Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials.

  2006cited by this paper
• Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration.

  2006cited by this paper
• Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease

  2006cited by this paper
• Use of Pegaptanib Sodium (Macugen®) for the Regression of Proliferative Diabetic Retinopathy

  2006cited by this paper
• Intravitreal injection of specific receptor tyrosine kinase inhibitor PTK787/ZK222 584 improves ischemia-induced retinopathy in mice

  2005cited by this paper
• A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema.

  2005influential reference
• Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema.

  2005cited by this paper
• Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress.

  2005cited by this paper
• Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration.

  2005cited by this paper
• Vitreous levels of vascular endothelial growth factor and stromal-derived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone.

  2004cited by this paper
• VEGF INHIBITION STUDY IN OCULAR NEOVASCULARIZATION CLINICAL TRIAL GROUP. PEGAPTANIB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

  2004cited by this paper
• The impact of diabetic retinopathy: perspectives from patient focus groups.

  2004cited by this paper
• Pegaptanib for neovascular age-related macular degeneration.

  2004cited by this paper
• Pharmacotherapy for diabetic retinopathy

  2004cited by this paper
• Global data on visual impairment in the year 2002.

  2004cited by this paper
• The prevalence of diabetic retinopathy among adults in the United States.

  2004cited by this paper
• Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives

  2003cited by this paper
• VEGF164-mediated Inflammation Is Required for Pathological, but Not Physiological, Ischemia-induced Retinal Neovascularization

  2003cited by this paper
• VEGF164 is proinflammatory in the diabetic retina.

  2003cited by this paper
• Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies.

  2003influential reference
• Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate.

  2002cited by this paper
• Diabetic retinopathy: more than meets the eye.

  2002cited by this paper
• Molecular understanding of hyperglycemia's adverse effects for diabetic complications.

  2002cited by this paper
• RELATIONSHIP BETWEEN VASCULAR ENDOTHELIAL GROWTH FACTOR AND INTERLEUKIN–6 IN DIABETIC RETINOPATHY

  2001cited by this paper
• The pathogenesis of edema in diabetic maculopathy.

  1999cited by this paper
• In vivo demonstration of increased leukocyte entrapment in retinal microcirculation of diabetic rats.

  1998cited by this paper
• Advanced glycation end products increase retinal vascular endothelial growth factor expression.

  1998cited by this paper
• VEGF induces hyperpermeability by a direct action on endothelial cells.

  1998cited by this paper
• VEGF localisation in diabetic retinopathy

  1998cited by this paper
• Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo.

  1996cited by this paper
• Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate.

  1996cited by this paper
• Hypoxic Induction of Endothelial Cell Growth Factors in Retinal Cells: Identification and Characterization of Vascular Endothelial Growth Factor (VEGF) as the Mitogen

  1995cited by this paper
• Hypoxic regulation of vascular endothelial growth factor in retinal cells.

  1995cited by this paper
• Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen.

  1995cited by this paper
• Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.

  1994cited by this paper
• Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy.

  1994cited by this paper
• Subretinal fibrosis after laser photocoagulation for diabetic macular edema.

  1992cited by this paper
• Submacular fibrosis after photocoagulation for diabetic macular edema.

  1992cited by this paper
• Contrast sensitivity changes in background diabetic retinopathy.

  1991cited by this paper
• Choroidal neovascularization after laser photocoagulation for diabetic macular edema.

  1990cited by this paper
• Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells.

  1989cited by this paper
• Vascular permeability factor, an endothelial cell mitogen related to PDGF.

  1989cited by this paper
• Vascular endothelial growth factor is a secreted angiogenic mitogen.

  1989cited by this paper
• Transient severe visual loss after panretinal photocoagulation.

  1988cited by this paper
• Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Early Treatment Diabetic Retinopathy Study Research Group.

  1987cited by this paper
• Intraretinal neovascularization in diabetic retinopathy.

  1984cited by this paper
• Clinical and experimental studies on retinal neovascularization. XXXIX Edward Jackson Memorial Lecture.

  1982cited by this paper
• Diabetic retinopathy, present and future. Conclusion of diabetic retinopathy symposium.

  1981cited by this paper
• Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group.

  1981cited by this paper
• Macular edema after scatter laser photocoagulation for proliferative diabetic retinopathy.

  1980cited by this paper
• Clinicopathologic correlations in diabetic retinopathy. I. Histology and fluorescein angiography of microaneurysms.

  1976cited by this paper
• Retinal vascular patterns. IV. Diabetic retinopathy.

  1961cited by this paper

• Identification of Hypoxia-Related Biomarkers for Proliferative Diabetic Retinopathy: An Integrative Bioinformatics Analysis

  2025cites this paper
• COMMONALITIES BETWEEN FIBROTIC AND INFLAMMATORY MECHANISMS IN PROLIFERATIVE VITREORETINOPATHY AND PROLIFERATIVE DIABETIC RETINOPATHY.

  2025cites this paper
• An Insight into the Development of Potential Antidiabetic Agents along with their Therapeutic Targets.

  2023cites this paper
• Application of Aptamer-based Hybrid Molecules in Early Diagnosis and Treatment of Diabetes Mellitus: From the Concepts Towards the Future.

  2019cites this paper
• Benefits of anti-vascular endothelial growth factor therapy for diabetic macular edema with and without vitreomacular adhesions

  2018influential citation
• Aptamers: novel diagnostic and therapeutic tools for diabetes mellitus and metabolic diseases

  2017cites this paper
• Vascular Endothelial Growth Factor Inhibitors for Diabetic Retinopathy

  2016cites this paper
• Aptamers as radiopharmaceuticals for nuclear imaging and therapy.

  2016cites this paper
• Overview of Ocular Anti-Vascular Endothelial Growth Factor Therapy in the Management of Diabetic Eye Complications

  2016cites this paper
• Updates in the Management of Diabetic Macular Edema

  2015cites this paper
• Aflibercept – Setting its Sights on Diabetic Macular Oedema

  2014influential citation
• Microvascular complications and diabetic retinopathy: recent advances and future implications.

  2013cites this paper
• Diabetic retinopathy: current and new treatment options.

  2012cites this paper
• Uveal metastatic disease: current and new treatment options (review).

  2011cites this paper
• Diabetic Vascular Complications & Inflammation - role of NFAT and TNFalpha

  2009cites this paper